SIRO Clinpharm seeks Asia Pacific growth with DreamCIS pact

Published: 10-Feb-2010
Regulatory Research & Development

Mumbai-based contract research organisation SIRO Clinpharm has formed an alliance with DreamCIS, a CRO based in Seoul, South Korea in order to build its business in the Asia Pacific region.


Mumbai-based contract research organisation SIRO Clinpharm has formed an alliance with DreamCIS, a CRO based in Seoul, South Korea in order to build its business in the Asia Pacific region.

DreamCIS has nearly a decade of experience in offering clinical research services to pharmaceutical companies and medical device manufacturers. Services include clinical trial management, pharmacovigilance, post marketing surveillance, data management, biostatistics and quality assurance services.

SIRO, which has a presence in India, Europe, and the US, has been involved in clinical research for 14 years and in addition to the services above, offers medical writing, clinical trials supplies management, feasibility and patient planning.

"Our goal is to offer a wider platform of patient recruitment capabilities from the Asia Pac region for our global client base," said Ajit Nair, Siro's president in India.




  • Companies:
  • SIRO Clinpharm Pvt Ltd
  • DreamCIS
See more

You may also like

Regulatory

SIRO Clinpharm expands its presence in Asia

Read more
Launches operations in Malaysia

Trending Articles

  1. Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
  2. IMed Consultancy helps Toby Orthopaedics navigate UK regulations Regulatory consultancy ensures compliance and confidence for Miami-based company
  3. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  4. Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
  5. Vetter strengthens senior management team for growth Three new managing directors to support global sustainable development

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Regulatory

SIRO Clinpharm expands its presence in Asia

Launches operations in Malaysia
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Manufacturing

Five critical design elements for Pelton wheel turbine flowmeters

Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Subscribe now